Literature DB >> 28462607

Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study.

Massimiliano Buoli1, Cecilia Maria Esposito1, Marco Godio2, Alice Caldiroli1, Marta Serati1, A Carlo Altamura1.   

Abstract

Available antipsychotics show different efficacy on manic symptoms of bipolar patients, but few studies have investigated the speed of action of the various compounds. For this reason, purpose of the present paper was to compare antipsychotic mono-therapies in terms of speed of action in a sample of manic bipolar patients. In total, 155 bipolar patients, treated with antipsychotic mono-therapy and followed-up in Inpatient Psychiatry Clinic of University of Milan, were included in this single-blind comparative study. Clinical response was defined as a reduction of Young Mania Rating Scale (YMRS) scores ⩾50%, while remission as a YMRS score <10. After 4 days patients who had been treated with asenapine, were more likely to have achieved a clinical response than those in treatment with haloperidol ( p = 0.001). After 7 days, a more frequent clinical response was achieved by patients treated with asenapine than those who had been treated with haloperidol ( p < 0.001) or olanzapine ( p = 0.047). Asenapine appears to be faster in determining treatment response in manic patients compared with haloperidol and less markedly with olanzapine.

Entities:  

Keywords:  Bipolar disorder; drugs for psychosis; mania; speed of action

Mesh:

Substances:

Year:  2017        PMID: 28462607     DOI: 10.1177/0269881117705098

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  3 in total

1.  Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases.

Authors:  Junqiu Zhai; Yu-E Wang; Xiangping Zhou; Yan Ma; Shixia Guan
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

2.  Quetiapine-Induced Hypomania and its Association with Quetiapine/Norquetiapine Plasma Concentrations: A Case Series of Bipolar Type 2 Patients.

Authors:  C Rovera; C M Esposito; V Ciappolino; D Cattaneo; S Baldelli; E Clementi; A C Altamura; M Buoli
Journal:  Drug Saf Case Rep       Date:  2017-10-23

Review 3.  A Review of Asenapine in the Treatment of Bipolar Disorder.

Authors:  Eduard Vieta; José Manuel Montes
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.